Florida Attorney General Joins Antitrust Lawsuit Against Suboxone Drugmaker

Follow CBSMIAMI.COM: Facebook | Twitter

TALLAHASSEE (CBSMiami/AP) — Florida Attorney General Pam Bondi joined thirty-five states and the District of Columbia in filing an antitrust lawsuit Thursday alleging that British drugmaker Indivior tried to keep cheaper, generic versions of Suboxone off the market, Bondi announced.

The complaint filed in the U.S. District Court for the Eastern District of Pennsylvania also names New Jersey's MonoSol Rx, a pharmaceutical dissolving-film company, for conspiring to corner the market on the popular medication used to treat people hooked on heroin and other painkillers.

According to the lawsuit, the company known today as Indivior was granted exclusive rights in 2002 to sell Suboxone tablets for seven years. When its rights expired, the company worked with MonoSol Rx to make an oral strip form of the drug that they then marketed as safer than tablets, the complaint said.

The attorneys general allege the conduct is illegal "product hopping," where a company makes small changes to a product to keep cheaper alternatives off the market, said Pennsylvania's Attorney General Bruce R. Beemer in a press release Thursday.

"When prescription drug companies unlawfully manipulate the marketplace to maximize profits, they put lives at risk and drive up the cost of health care for everyone," said California's Attorney General Kamala Harris in a statement.

Representatives of the two companies were not immediately available for comment.

(TM and © Copyright 2016 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2016 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.)

Read more
f

We and our partners use cookies to understand how you use our site, improve your experience and serve you personalized content and advertising. Read about how we use cookies in our cookie policy and how you can control them by clicking Manage Settings. By continuing to use this site, you accept these cookies.